Browsing Tag
EyePoint Inc.
2 posts
LUGANO failure wipes billions from EyePoint valuation as LUCIA becomes decisive
DURAVYU misses its first Phase 3 wet AMD endpoint as EyePoint shares plunge nearly 70%, making the Q4 LUCIA readout a critical catalyst.
EyePoint reaches full DME enrollment with $222.5m and a runway ending near the readout
EyePoint completes Phase 3 DME enrollment as DURAVYU targets six-month dosing, with wet AMD data due in August and DME results in late 2027.